Última actualización 12 de julio de 2026
Key finding
mean difference 7.46%, 95% CI 1.67% to 13.25%; p = 0.01
This study evaluated the impact of continuous glucose monitoring (CGM) on glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes, finding significant improvements in time in range.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of continuous glucose monitoring (CGM) on glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes, finding significant improvements in time in range.
Improved glycaemic control is crucial for patients with chronic pancreatitis and diabetes, as it can reduce the risk of complications associated with poor glucose management. This study suggests that continuous glucose monitoring could be a valuable tool in managing diabetes for these patients, potentially leading to better health outcomes and quality of life.
Effectiveness of interventions was unclear for some outcomes. The study may not be generalizable to all diabetes populations. Sample size and demographic details were not specified.
Published in
Publication details and source links for this paper.
Line D, Simon LC, Peter BS, et al. Continuous glucose monitoring improves glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes. Diabetes, Obesity & Metabolism. 2025;27(6):3379-3388. doi:10.1111/dom.16356
CGM improved time in range (3.9–10.0 mmol/L) by 7.46% (p = 0.01).
CGM reduced time above range (>10.0 mmol/L) by 6.55% (p = 0.04).
CGM reduced time below range (<3.9 mmol/L) by 0.91% (p = 0.04).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Continuous glucose monitoring, Self-monitoring of blood glucose and Hypoglycemia events, Percentage of time spent with sensor glucose levels <3.9 mmol/L, Time above range, and 1 more.
This study contributes evidence to
Primary intervention
Continuous glucose monitoring
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
373
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Continuous glucose monitoring → Hypoglycemia events
Continuous glucose monitoring → Hypoglycemia events
Continuous glucose monitoring → Percentage of time spent with sensor glucose levels <3.9 mmol/L
Continuous glucose monitoring → Percentage of time spent with sensor glucose levels <3.9 mmol/L
Continuous glucose monitoring → Time above range
Continuous glucose monitoring → Time above range
Continuous glucose monitoring → Time in range
Continuous glucose monitoring → Time in range
Self-monitoring of blood glucose → Hypoglycemia events
Self-monitoring of blood glucose → Hypoglycemia events
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and CGM Time in Range.
This study contributes to the evidence on the following intervention-outcome relationships.
Devices & Technology
Devices & Technology
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on Insulin Delivery Systems
Contributes to Insulin Delivery Systems evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
6 results
3 results
6 results
6 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Delivery Systems may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Strong | EvidenceScore™ 83.4 | moderate positive | ConsistencyScore™ Consistent | 1 study
Time above range
EvidenceScore™ Strong | EvidenceScore™ 78.6 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 17 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Delivery Systems may improve Hypoglycemia.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Self-monitoring of blood glucose for Hypoglycemia events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Continuous glucose monitoring may worsen Percentage of time spent with sensor glucose levels <3.9 mmol/L or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of time spent with sensor glucose levels <3.9 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
